Last Updated: 2026

Rhythm Pharmaceuticals

Rank#2935

Market Cap5.61B

CountryUnited States

Summary

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

History

Rhythm Pharmaceuticals, Inc. was founded in 2010 by Jerold Williams and Carl Gordon and has been led by industry veteran, Keith Gottesdiener, MD, as CEO since 2010. The company is headquartered in Boston, MA and has a presence in Watertown, MA, San Francisco, CA and Deerfield, IL.

Mission

We are passionate about bringing transformational treatments to people with rare genetic disorders so they may live healthier and more fulfilling lives.

Vision

To be the leading rare disease therapeutics company dedicated to the discovery and development of innovative treatments to honor the unique needs of patients living with genetic and metabolic disorders.

References

https://in.investing.com/equities/rhythm-pharma

https://finance.yahoo.com/quote/RYTM/profile?p=RYTM

https://www.crunchbase.com/organization/rhythm-pharmaceuticals-2

https://sec.report/CIK/0001649904

https://companiesmarketcap.com/

https://www.rhythmtx.com

Leadership team

Dr. David P. Meeker M.D. (Chairman, Pres & CEO)

Mr. Hunter C. Smith M.B.A. (CFO & Treasurer)

Mr. Joseph Shulman (Chief Technical Officer)

Products / Services

Biotechnology, Pharmaceutical, Therapeutics

Number of Employees

100 - 500

Address

Boston, Massachusetts, United States

Established

2010-01-01

Company Registration

SEC CIK number: 0001649904

Revenue

5M - 20M

Traded as

RYTM

Website

https://www.rhythmtx.com

Social Media

Last Updated: 2026

Rhythm Pharmaceuticals

Rank#2935

Market Cap5.61B

CountryUnited States

Summary

History

Mission

We are passionate about bringing transformational treatments to people with rare genetic disorders so they may live healthier and more fulfilling lives.

Vision

References

https://in.investing.com/equities/rhythm-pharma

https://finance.yahoo.com/quote/RYTM/profile?p=RYTM

https://www.crunchbase.com/organization/rhythm-pharmaceuticals-2

https://sec.report/CIK/0001649904

https://companiesmarketcap.com/

https://www.rhythmtx.com

Leadership team

Dr. David P. Meeker M.D. (Chairman, Pres & CEO)

Mr. Hunter C. Smith M.B.A. (CFO & Treasurer)

Mr. Joseph Shulman (Chief Technical Officer)